Comparison efficacy and safety of Andrographis paniculata extract capsules and placebo in COVID-19 patients: Double blind randomized control trial
Phase 2
Completed
- Conditions
- COVID-19 patient with asymptomatic and mild symptomatic. Progression score between 0-3. (Green color)COVID-19Andrographolide
- Registration Number
- TCTR20210809004
- Lead Sponsor
- Thammasat university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 186
Inclusion Criteria
1. Covid-19 was diagnosed within 5 day before admission in field hospital
2. Patients have asymptomatic or mild symptoms (Score is 0-3 according to WHO progression scale)
Exclusion Criteria
1. high fever (BT> 38.5 Celcius)
2. Chest X-ray was found an abnormality
3. The clinical symptoms present to pneumonia and SpO2 less than 96%
4. Started anti-viral drug before screening
5. AST and ALT more than 1.5 times of upper normal limit
6. Patient has hypersensitivity history to Andrographis
7. during on anti - coagulants drug
8. patient has serious medical condition including COPD, TB, Renal failure, heart failure, liver disease, immunodeficiancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Symptoms everyday during on intervention VAS,severity score follow until discharge WHO progression scale
- Secondary Outcome Measures
Name Time Method Genomic intregrity Day 7 and Day 14 after RT-PCR show positive report Mass array